Allogene Therapeutics
ALLO
116 hedge funds and large institutions have $1.86B invested in Allogene Therapeutics in 2019 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 11 closing their positions.
191% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 11
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
22% more funds holding
Funds holding: 95 → 116 (+21)
2.33% more ownership
Funds ownership: 56.42% → 58.75% (+2.3%)
5% more call options, than puts
Call options by funds: $3.11M | Put options by funds: $2.97M
1% less capital invested
Capital invested by funds: $1.87B → $1.86B (-$11.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ROTUOC
Regents of the University of California
Oakland,
California
|
+$64.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$34.9M |
| 3 |
BlackRock
New York
|
+$28.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.24M |
| 5 |
WCM
Wildcat Capital Management
New York
|
+$8.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VV Manager
Boston,
Massachusetts
|
-$33M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$11.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.13M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$8.21M |
ALLO Hedge Fund Activity: Q4 2019 in Review
116 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2019, worth a combined $1.86B — down 0.62% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ALLO positions and 11 closed out — a net gain of 21 holders — while 38 added to existing stakes and 26 trimmed.
The largest buyer was Regents of the University of California, opening a new position worth an estimated $64.7M. The largest seller was VV Manager, cutting an estimated $33M.
- 116 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2019, up from 95 in Q3 2019.
- Funds reported $1.86B of Allogene Therapeutics stock for Q4 2019, down 0.62% quarter-over-quarter.
- 32 funds opened new Allogene Therapeutics positions in Q4 2019 and 11 closed out, a net change of +21 holders.
- The largest Allogene Therapeutics buyer in Q4 2019 was Regents of the University of California, an estimated $64.7M added.
- The largest Allogene Therapeutics seller in Q4 2019 was VV Manager, an estimated $33M sold.
Based on aggregated 13F filings for Q4 2019.